Bortezomib and Thalidomide Associated with Pulmonary Function Abnormalities in Myeloma Patients

Share this content:
(ChemotherapyAdvisor) – Bortezomib and thalidomide might be associated with the development of pulmonary function abnormalities among patients with multiple myeloma who are administered these immunodulatory agents prior to autologous stem cell transplantation, according to a study published in Clinical Lymphoma, Myeloma & Leukemia.

“We describe a 2-fold increased odds of PFT [pulmonary function test] abnormalities with novel agents when used before transplantation – obstruction for bortezomib-exposed patients and restriction for thalidomide-exposed patients,” reported lead author Jarrod T. Bruce, MD, a clinical assistant professor at the Division of Pulmonary, Allergy, Critical Care and Sleep Medicine at the Ohio state Medical Center in Columbus Ohio, and coauthors.

Pulmonary restriction involves reduced maximum achievable lung volume at peak inhalation. Respiratory obstruction refers to impeded airflow during inhalation or expiration.

“Our data suggest clinicians should have a low threshold of suspicion for pulmonary abnormalities in patients exposed to bortezomib and thalidomide,” Dr. Bruce and coauthors advised.  

The authors reviewed medical records for 343 myeloma patients who had been administered pulmonary function tests prior to autologous stem cell transplantation. Of these patients, 234 had received bortezomib and/or lenalidomide and/or thalidomide.

Patients who were administered bortezomib were more likely to suffer obstructive PFT (19.8%) than were patients who had not received bortezomib (9.9%; P =0.015), whereas patients who had been administered thalidomide were more likely to suffer restrictive PFT (30.3%) compared with those who had not received thalidomide (18.4%; P=0.17).

After adjusting for age, sex, Durie-Salmon (DS) stage, BMI, time from diagnosis to transplantation, and smoking history, the odds of obstructive PFT among patients administered bortezomib were nearly twice as high as those seen among patients not receiving bortezomib (OR 1.96 [95% CI: 1.01-3.79]; P=0.047).  Thalidomide-associated pulmonary restriction also remained statistically significant (OR 1.97 [95% CI: 1.13-3.44];P=0.017).

Lenalidomide exposure was not associated with pulmonary function abnormalities and did not modulate the associations between pulmonary function and thalidomide or bortezomib.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs